Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Compare

1,209 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RARE Analyst Ratings

Strong Buy

20 Buy

1 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Ultragenyx

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RARE Stock 12 Month Forecast

Average Price Target

$54.32

▲(154.55% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $54.32 with a high forecast of $84.00 and a low forecast of $25.00. The average price target represents a 154.55% change from the last price of $21.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","85":"$85","37.75":"$37.8","53.5":"$53.5","69.25":"$69.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$84.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$54.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,37.75,53.5,69.25,85],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.02,27.71076923076923,32.401538461538465,37.09230769230769,41.78307692307692,46.473846153846154,51.16461538461539,55.85538461538461,60.54615384615384,65.23692307692308,69.92769230769231,74.61846153846153,79.30923076923077,{"y":84,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.02,25.427692307692308,27.835384615384616,30.24307692307692,32.65076923076923,35.058461538461536,37.466153846153844,39.87384615384615,42.28153846153846,44.68923076923077,47.096923076923076,49.504615384615384,51.91230769230769,{"y":54.32,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.02,23.17230769230769,23.324615384615385,23.476923076923075,23.62923076923077,23.78153846153846,23.933846153846154,24.086153846153845,24.23846153846154,24.39076923076923,24.543076923076924,24.695384615384615,24.847692307692306,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.97,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$84.00

Average Price Target$54.32

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Benjamin Burnett

Wells Fargo

$45

Buy

110.87%

Upside

Reiterated

03/13/26

Analysts Conflicted on These Healthcare Names: Immutep (NASDAQ: IMMP) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Anupam Rama

J.P. Morgan

$120→$74

Buy

246.77%

Upside

Reiterated

03/12/26

Ultragenyx price target lowered to $74 from $120 at JPMorganUltragenyx price target lowered to $74 from $120 at JPMorgan

Tazeen Ahmad

Bank of America Securities

$57→$51

Buy

138.99%

Upside

Reiterated

03/12/26

Analysts Are Bullish on Top Healthcare Stocks: Elicio Therapeutics (ELTX), Silence Therapeutics (SLN)

Ram Selvaraju

H.C. Wainwright

$50

Buy

134.30%

Upside

Reiterated

02/24/26

Analysts Are Bullish on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Vir Biotechnology (VIR)

Whitney Ijem

Canaccord Genuity

$128→$79

Buy

270.20%

Upside

Reiterated

02/17/26

Canaccord Genuity Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Gavin Clark-Gartner

Evercore ISI

$39→$34

Buy

59.33%

Upside

Reiterated

02/17/26

Ultragenyx price target lowered to $37 from $39 at Evercore ISIUltragenyx price target lowered to $37 from $39 at Evercore ISI

Laura Chico

Wedbush

$23→$25

Hold

17.15%

Upside

Reiterated

02/17/26

Wedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

Joon Lee

Truist Financial

$90→$76

Buy

256.14%

Upside

Reiterated

02/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Yaron Werber

TD Cowen

$75→$49

Buy

129.62%

Upside

Reiterated

02/13/26

TD Cowen Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Sami Corwin

William Blair

―

Buy

―

Reiterated

02/13/26

Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (NASDAQ: VTGN) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Salveen Richter

Goldman Sachs

$71→$61

Buy

185.85%

Upside

Reiterated

02/13/26

Goldman Sachs Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Yigal Nochomovitz

Citi

$50→$45

Buy

110.87%

Upside

Reiterated

02/13/26

Ultragenyx price target lowered to $45 from $50 at CitiUltragenyx price target lowered to $45 from $50 at Citi

Jack Allen

Robert W. Baird

$47→$40

Buy

87.44%

Upside

Reiterated

02/13/26

Ultragenyx price target lowered to $40 from $47 at BairdUltragenyx price target lowered to $40 from $47 at Baird

Kristen Kluska

Cantor Fitzgerald

$84

Buy

293.63%

Upside

Reiterated

02/12/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Luca Issi

RBC Capital

$35

Buy

64.01%

Upside

Reiterated

02/12/26

RBC Capital Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Benjamin Burnett

Wells Fargo

$45

Buy

110.87%

Upside

Reiterated

03/13/26

Analysts Conflicted on These Healthcare Names: Immutep (NASDAQ: IMMP) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Anupam Rama

J.P. Morgan

$120→$74

Buy

246.77%

Upside

Reiterated

03/12/26

Ultragenyx price target lowered to $74 from $120 at JPMorganUltragenyx price target lowered to $74 from $120 at JPMorgan

Tazeen Ahmad

Bank of America Securities

$57→$51

Buy

138.99%

Upside

Reiterated

03/12/26

Analysts Are Bullish on Top Healthcare Stocks: Elicio Therapeutics (ELTX), Silence Therapeutics (SLN)

Ram Selvaraju

H.C. Wainwright

$50

Buy

134.30%

Upside

Reiterated

02/24/26

Analysts Are Bullish on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Vir Biotechnology (VIR)

Whitney Ijem

Canaccord Genuity

$128→$79

Buy

270.20%

Upside

Reiterated

02/17/26

Canaccord Genuity Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Gavin Clark-Gartner

Evercore ISI

$39→$34

Buy

59.33%

Upside

Reiterated

02/17/26

Ultragenyx price target lowered to $37 from $39 at Evercore ISIUltragenyx price target lowered to $37 from $39 at Evercore ISI

Laura Chico

Wedbush

$23→$25

Hold

17.15%

Upside

Reiterated

02/17/26

Wedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

Joon Lee

Truist Financial

$90→$76

Buy

256.14%

Upside

Reiterated

02/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Yaron Werber

TD Cowen

$75→$49

Buy

129.62%

Upside

Reiterated

02/13/26

TD Cowen Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Sami Corwin

William Blair

―

Buy

―

Reiterated

02/13/26

Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (NASDAQ: VTGN) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Salveen Richter

Goldman Sachs

$71→$61

Buy

185.85%

Upside

Reiterated

02/13/26

Goldman Sachs Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Yigal Nochomovitz

Citi

$50→$45

Buy

110.87%

Upside

Reiterated

02/13/26

Ultragenyx price target lowered to $45 from $50 at CitiUltragenyx price target lowered to $45 from $50 at Citi

Jack Allen

Robert W. Baird

$47→$40

Buy

87.44%

Upside

Reiterated

02/13/26

Ultragenyx price target lowered to $40 from $47 at BairdUltragenyx price target lowered to $40 from $47 at Baird

Kristen Kluska

Cantor Fitzgerald

$84

Buy

293.63%

Upside

Reiterated

02/12/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Luca Issi

RBC Capital

$35

Buy

64.01%

Upside

Reiterated

02/12/26

RBC Capital Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ultragenyx Pharmaceutical

3 Months

xxx

Success Rate

14/23 ratings generated profit

Average Return

+1.09%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +1.09% per trade.

1 Year

Whitney IjemCanaccord Genuity

Success Rate

6/14 ratings generated profit

Average Return

-10.44%

reiterated a buy rating 28 days ago

Copying Whitney Ijem's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -10.44% per trade.

2 Years

xxx

Success Rate

12/33 ratings generated profit

Average Return

-4.35%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 36.36% of your transactions generating a profit, with an average return of -4.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RARE Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RARE has received 37 Buy Ratings, 34 Hold Ratings, and 2 Sell Ratings. RARE average Analyst price target in the past 3 months is 54.32.

Each month's total comprises the sum of three months' worth of ratings.

RARE Financial Forecast

RARE Earnings Forecast

Next quarter’s earnings estimate for RARE is -$1.43 with a range of -$2.01 to -$1.01. The previous quarter’s EPS was -$1.29. RARE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.

RARE Sales Forecast

Next quarter’s sales forecast for RARE is $163.96M with a range of $129.00M to $183.86M. The previous quarter’s sales results were $207.00M. RARE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.

RARE Stock Forecast FAQ

What is RARE’s average 12-month price target, according to analysts?

Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is 54.32.

What is RARE’s upside potential, based on the analysts’ average price target?

Ultragenyx Pharmaceutical has 154.55% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RARE a Buy, Sell or Hold?

Ultragenyx Pharmaceutical has a consensus rating of Strong Buy which is based on 20 buy ratings, 1 hold ratings and 0 sell ratings.

What is Ultragenyx Pharmaceutical’s price target?

The average price target for Ultragenyx Pharmaceutical is 54.32. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $84.00 ,the lowest forecast is $25.00. The average price target represents 154.55% Increase from the current price of $21.34.

What do analysts say about Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of RARE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

RARE Analyst Ratings

RARE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ultragenyx Pharmaceutical

RARE Analyst Recommendation Trends

RARE Financial Forecast

RARE Earnings Forecast

RARE Sales Forecast

RARE Stock Forecast FAQ

Detailed List of Analyst Forecasts